In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


REMS 2.0: FDA Refining New Drug Safety Tools

This article was originally published in RPM Report

Executive Summary

FDA’s new post-marketing risk management authorities are receiving much more public attention in the context of the Avandia decision…but use of the REMS is actually declining. As FDAAA turns 3, it is clear that REMS are going through some growing pains. The new tools will be refined—but they are definitely here to stay.

Related Content

A Transparency Case Study: Horizant Approval for RLS Offers Window Into Complexity of Complete Response Disclosures
Controlling Opioids: REMS Meets Congressional Resistance
The Era of Drug Efficacy
The New Drug Safety Committee Members
Oral Molecules In An Injectable World: What Developers Need To Do Now
Transmucosal Fentanyl Products Become First Plug-and-Play REMS
FDAAA Impact (Year Two): More of Everything
Waking Up to REMS (Part 3): Redefining Marketing
FDAAA Impact Analysis: Year One
The REMS Era Begins: FDA Applies Soft Touch With New Drug Safety Tools


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts